614 related articles for article (PubMed ID: 34492682)
1. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.
Wieduwilt MJ; Yin J; Wetzler M; Uy GL; Powell BL; Kolitz JE; Liedtke M; Stock W; Beumer JH; Mattison RJ; Storrick E; Christner SM; Lewis LD; Devine S; Stone RM; Larson RA
Blood Adv; 2021 Nov; 5(22):4691-4700. PubMed ID: 34492682
[TBL] [Abstract][Full Text] [Related]
2. Frontline combination of dasatinib and low-intensity chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia.
Peng Y; Huang J; Yin J; Meng F; Cao Y; Huang L; Li D; Zhang Y; Zhang D; Meng L; Han Z; Hong Z
Expert Rev Hematol; 2024; 17(4-5):173-180. PubMed ID: 38616308
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
Rousselot P; Coudé MM; Gokbuget N; Gambacorti Passerini C; Hayette S; Cayuela JM; Huguet F; Leguay T; Chevallier P; Salanoubat C; Bonmati C; Alexis M; Hunault M; Glaisner S; Agape P; Berthou C; Jourdan E; Fernandes J; Sutton L; Banos A; Reman O; Lioure B; Thomas X; Ifrah N; Lafage-Pochitaloff M; Bornand A; Morisset L; Robin V; Pfeifer H; Delannoy A; Ribera J; Bassan R; Delord M; Hoelzer D; Dombret H; Ottmann OG;
Blood; 2016 Aug; 128(6):774-82. PubMed ID: 27121472
[TBL] [Abstract][Full Text] [Related]
4. [Clinical Analysis of Dasatinib and Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia].
Li Y; Wang BJ; Liu W; Liang ZY; Yin Y; Dong YJ; Wang Q; Sun YH; Xu WL; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):18-23. PubMed ID: 32027247
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
[TBL] [Abstract][Full Text] [Related]
6. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
Morita K; Kantarjian HM; Sasaki K; Issa GC; Jain N; Konopleva M; Short NJ; Takahashi K; DiNardo CD; Kadia TM; Garcia-Manero G; Daver N; Montalban Bravo G; Cortes JE; Ravandi F; Jabbour E
Cancer; 2021 Aug; 127(15):2641-2647. PubMed ID: 33823073
[TBL] [Abstract][Full Text] [Related]
7. [Dasatinib combined with multi-agent chemotherapy regimen in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective study from a single center].
Zhang GJ; Gong XY; Qiu SW; Zhou CL; Liu KQ; Lin D; Liu BC; Wei H; Wei SN; Li Y; Gu RX; Gong BF; Liu YT; Fang QY; Mi YC; Wang Y; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):109-115. PubMed ID: 33858040
[No Abstract] [Full Text] [Related]
8. Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study.
Zhu Y; Zhu Y; Miao L; Jia T; Mao J; Xue L; Wang Y
Technol Cancer Res Treat; 2023; 22():15330338231165866. PubMed ID: 36959735
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yoon JH; Yhim HY; Kwak JY; Ahn JS; Yang DH; Lee JJ; Kim SJ; Kim JS; Park SJ; Choi CW; Eom HS; Park SK; Choi SY; Kim SH; Kim DW; Lee S
Ann Oncol; 2016 Jun; 27(6):1081-1088. PubMed ID: 26951627
[TBL] [Abstract][Full Text] [Related]
10. Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation.
Chen H; Xu LP; Zhang XH; Wang Y; Chen YH; Yan CH; Cheng YF; Han W; Chen Y; Qin YZ; Liu Y; Chang YJ; Liu KY; Huang XJ
Leuk Res; 2022 Oct; 121():106930. PubMed ID: 36007342
[TBL] [Abstract][Full Text] [Related]
11. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XY; Han W; Zhang XH; Wang Y; Zhang YY; Qin YZ; Liu YR; Huang XJ
J Hematol Oncol; 2012 Jun; 5():29. PubMed ID: 22682059
[TBL] [Abstract][Full Text] [Related]
12. The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.
Tachibana T; Najima Y; Akahoshi Y; Hirabayashi S; Harada K; Doki N; Uchida N; Fukuda T; Sawa M; Ogata M; Takada S; Tanaka M; Matsuhashi Y; Tanaka J; Onizuka M; Ichinohe T; Atsuta Y; Kako S;
Ann Hematol; 2020 Oct; 99(10):2393-2404. PubMed ID: 32803312
[TBL] [Abstract][Full Text] [Related]
13. A multicenter total therapy strategy for
Chiaretti S; Ansuinelli M; Vitale A; Elia L; Matarazzo M; Piciocchi A; Fazi P; Di Raimondo F; Santoro L; Fabbiano F; Califano C; Martinelli G; Ronco F; Ferrara F; Cascavilla N; Bigazzi C; Tedeschi A; Sica S; Di Renzo N; Melpignano A; Beltrami G; Vignetti M; Foa R
Haematologica; 2021 Jul; 106(7):1828-1838. PubMed ID: 33538150
[TBL] [Abstract][Full Text] [Related]
14. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.
Bachanova V; Marks DI; Zhang MJ; Wang H; de Lima M; Aljurf MD; Arellano M; Artz AS; Bacher U; Cahn JY; Chen YB; Copelan EA; Drobyski WR; Gale RP; Greer JP; Gupta V; Hale GA; Kebriaei P; Lazarus HM; Lewis ID; Lewis VA; Liesveld JL; Litzow MR; Loren AW; Miller AM; Norkin M; Oran B; Pidala J; Rowe JM; Savani BN; Saber W; Vij R; Waller EK; Wiernik PH; Weisdorf DJ
Leukemia; 2014 Mar; 28(3):658-65. PubMed ID: 23989431
[TBL] [Abstract][Full Text] [Related]
15. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Czyz A; Lewandowski K; Kroll R; Komarnicki M
Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
[TBL] [Abstract][Full Text] [Related]
17. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Foà R; Bassan R; Vitale A; Elia L; Piciocchi A; Puzzolo MC; Canichella M; Viero P; Ferrara F; Lunghi M; Fabbiano F; Bonifacio M; Fracchiolla N; Di Bartolomeo P; Mancino A; De Propris MS; Vignetti M; Guarini A; Rambaldi A; Chiaretti S;
N Engl J Med; 2020 Oct; 383(17):1613-1623. PubMed ID: 33085860
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.
Yoon JH; Min GJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
Cancer; 2019 Mar; 125(6):873-883. PubMed ID: 30521062
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sugiura I; Doki N; Hata T; Cho R; Ito T; Suehiro Y; Tanaka M; Kako S; Matsuda M; Yokoyama H; Ishikawa Y; Taniguchi Y; Hagihara M; Ozawa Y; Ueda Y; Hirano D; Sakura T; Tsuji M; Kamae T; Fujita H; Hiramoto N; Onoda M; Fujisawa S; Hatta Y; Dobashi N; Nishiwaki S; Atsuta Y; Kobayashi Y; Hayakawa F; Ohtake S; Naoe T; Miyazaki Y
Blood Adv; 2022 Jan; 6(2):624-636. PubMed ID: 34516628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
